Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
Thursday, August 08, 2024Vertex Pharmaceuticals announced today a reimbursement agreement with NHS England for eligible transfusiondependent beta thalassemia TDT patients to access the CRISPRCas
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Wednesday, August 07, 2024Quoin Pharmaceuticals Ltd a clinical stage specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases today announced the planned initiation of an investigatorled clinical study in New Zea...
Levicept Announces Positive Results of Phase II Trial of novel Neurotrophin-3 Inhibitor, LEVI-04, for the Treatment of Patients with Moderate to Severe Osteoarthritis
Tuesday, August 06, 2024Levicept Ltd a biotechnology company focused on the development of LEVI a firstinclass treatment for osteoarthritis and other pain indications today announces positive results from its Phase II trial of LEVI a novel and first in class neurotrophin
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Monday, August 05, 2024Rezolute Inc a latestage biopharmaceutical company committed to developing novel transformative therapies for serious rare diseases
Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)
Saturday, August 03, 2024Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of oncology autoimmune cardiovascular and metabolic
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
Friday, August 02, 2024Daiichi Sankyo and Merck known as MSD outside of the United States and Canada today announced that the first patient has been dosed in the IDeateLung phase trial evaluating the efficacy and safety of investigational ifinatamab
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
Friday, August 02, 2024Vir Biotechnology Inc today announced that it has entered into an exclusive worldwide license agreement with Sanofi for three clinicalstage masked Tcell
FDA Accepted PD-L1 Inhibitor Durvalumab for the Treatment of Endometrial Cancer
Friday, August 02, 2024On June the US FDA approved AstraZenecas Durvalumab IMFINZI for primary advanced or recurrent endometrial cancer with mismatch repair deficiency Endometrial cancer is the most prevalent gynecologic cancer with an estimated new US cases in This ap...
FDA Approves AChEI ALPHA-1062 for Alzheimer’s Disease Treatment
Friday, August 02, 2024On July the US FDA approved Alpha Cognition Incs ALPHA Zunveyl an Acetylcholinesterase AChE inhibitor for treating mildtomoderate Alzheimers disease This condition affects approximately million people in the United States Over of physicians are d...
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
Thursday, August 01, 2024AbCellera announced today that it has expanded its existing collaboration with Eli Lilly and Company to discover therapeutic antibodies for programs in immunology cardiovascular disease and neuroscience The expansion builds upon
